Market Cap : 1.79 B | Enterprise Value : 1.54 B | PE Ratio : | PB Ratio : 5.06 |
---|
NAS:TVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:TVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Travere Therapeutics's enterprise value is $1,541.6 Mil. Travere Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2020 was $194.0 Mil. Therefore, Travere Therapeutics's EV-to-Revenue for today is 7.95.
During the past 9 years, the highest EV-to-Revenue of Travere Therapeutics was 17396.70. The lowest was 1.60. And the median was 4.50.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2021-02-25), Travere Therapeutics's stock price is $29.950000. Travere Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 was $4.27. Therefore, Travere Therapeutics's PS Ratio for today is 7.02.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where Travere Therapeutics's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Travere Therapeutics's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 1541.634 | / | 194.025 | |
= | 7.95 |
Travere Therapeutics's current Enterprise Value is $1,541.6 Mil.
Travere Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2020 was 46.687 (Dec. 2019 ) + 47.769 (Mar. 2020 ) + 48.43 (Jun. 2020 ) + 51.139 (Sep. 2020 ) = $194.0 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Travere Therapeutics's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 29.950000 | / | 4.267 | |
= | 7.02 |
Travere Therapeutics's share price for today is $29.950000.
Travere Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 was 1.085 (Dec. 2019 ) + 1.096 (Mar. 2020 ) + 1.082 (Jun. 2020 ) + 1.004 (Sep. 2020 ) = $4.27.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
No Headline